EGFR and non-small cell lung carcinoma: In a phase III randomized trial (AURA3), involving patients with EGFR p.T790M-positive metastatic NSCLC progressing after first-line treatment, the objective response rate was significantly superior with osimertinib (71%) compared to chemotherapy (31%).